Evidence map›Paper›PMID 22820867›Full record

ArticlePsychopharmacology2013

Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.

Albert Ferrés-Coy, Noemí Santana, Anna Castañé, Roser Cortés, María C Carmona, Miklos Toth, Andrés Montefeltro, Francesc Artigas, Analía Bortolozzi

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Pivotal mental states.Journal of psychopharmacology (Oxford, England) · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Serotonin and brain function: a tale of two receptors.Journal of psychopharmacology (Oxford, England) · 2017
    Review
  16. Blunted 5-HTPsychopharmacology · 2017
    Article
  17. Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Article
  18. A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Albert Ferrés-CoyDepartment of Neurochemistry and Neuropharmacology, IIBB-CSIC-IDIBAPS, C/ Roselló 161, 6th floor, 08036 Barcelona, Spain.
Noemí Santana
Anna Castañé
Roser Cortés
María C Carmona
Miklos Toth
Andrés Montefeltro
Francesc Artigas
Analía Bortolozzi
Centro de Investigación Biomédica en Red de Salud Mental · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstitut d'Investigacions Biomèdiques de Barcelona · ESCornell University · US

Funding

Non-Genetic Transmission of Genetic Risk: Mechanism and Relevance to PsychiatricR01MH086883 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI TOTH, MIKLOS · 2009 to 2012
$1.3M
6 · The paper itself

Abstract

rationaleIdentifying the etiological factors in anxiety and depression is critical to develop more efficacious therapies. The inhibitory serotonin(1A) receptors (5-HT(1A)R) located on 5-HT neurons (autoreceptors) limit antidepressant responses and their expression may be increased in treatment-resistant depressed patients.

objectivesRecently, we reported that intranasal administration of modified small interference RNA (siRNA) molecules targeting 5-HT(1A)R in serotonergic neurons evoked antidepressant-like effects. Here we extended this finding using marketed siRNAs against 5-HT(1A)R (1A-siRNA) to reduce directly the 5-HT(1A) autoreceptor expression and evaluate its biological consequences under basal conditions and in response to stressful situations.

methodsAdult mice were locally infused with vehicle, nonsense siRNA, and 1A-siRNA into dorsal raphe nucleus (DR). 5-HT(1A)R knockout mice (1A-KO) were also used. Histological approaches, in vivo microdialysis, and stress-related behaviors were performed to assess the effects of 5-HT(1A) autoreceptor knockdown.

resultsIntra-DR 1A-siRNA infusion selectively reduced 5-HT(1A)R mRNA and binding levels and canceled 8-OH-DPAT-induced hypothermia. Basal extracellular 5-HT in medial prefrontal cortex (mPFC) did not differ among treatments. However, 1A-siRNA-treated mice displayed less immobility in the tail suspension and forced swim tests, as did 1A-KO mice. This was accompanied by a greater increase in prefrontal 5-HT release during tail suspension test. Moreover, intra-DR 1A-siRNA infusion augmented the increase of extracellular 5-HT in mPFC evoked by fluoxetine, up to the level in 1A-KO mice.

conclusionTogether with our previous report, the present results indicate that acute suppression of 5-HT(1A) autoreceptor expression evokes robust antidepressant-like effects, likely mediated by an increased capacity of serotonergic neurons to release 5-HT in stressful conditions.

Indexed as

8-Hydroxy-2-(di-n-propylamino)tetralinAnimalsAutoreceptorsBehavior, AnimalDisease Models, AnimalFluoxetineGene Knockdown TechniquesHypothermiaMaleMiceMice, Inbred C57BLMice, KnockoutMicrodialysisPrefrontal CortexRaphe NucleiReceptor, Serotonin, 5-HT1A8-Hydroxy-2-(di-n-propylamino)tetralinAutoreceptorsFluoxetineReceptor, Serotonin, 5-HT1ARNA, MessengerRNA, Small InterferingSelective Serotonin Reuptake InhibitorsSerotonin

Identifiers

PMID22820867
OpenAlexW2077908152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.